Cc Peptide

Lab Reagents

Cc Laboratories manufactures the cc peptide reagents distributed by Genprice. The Cc Peptide reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Cc. Other Cc products are available in stock. Specificity: Cc Category: Peptide

Lab Tools information

CC-90003

B2419-5 each
EUR 496.8

CC-115

B2499-25 each
EUR 757.2

CC-115

B2499-5 each
EUR 235.2

Lenalidomide (CC-5013)

A4211-100 100 mg
EUR 226.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)

A4211-250 250 mg
EUR 268.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)

A4211-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)

A4211-50 50 mg
EUR 184.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)

A4211-500 500 mg
EUR 309.6
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)

A4211-S Evaluation Sample
EUR 97.2
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Pomalidomide (CC-4047)

A4212-10 10 mg
EUR 170.4
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)

A4212-200 200 mg
EUR 964.8
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)

A4212-5 5 mg
EUR 129.6
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)

A4212-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)

A4212-50 50 mg
EUR 351.6
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)

A4212-S Evaluation Sample
EUR 97.2
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Apremilast (CC-10004)

A4317-10 10 mg
EUR 268.8
Description: Apremilast, also known as CC-10004, is a novel and potent small-molecule inhibitor of phosphodiesterase 4 (PDE4), a key enzyme involved in cyclic adenosine monophosphate (cAMP) degradation and cytokine production of inflammatory cells.

Apremilast (CC-10004)

A4317-25 25 mg
EUR 338.4
Description: Apremilast, also known as CC-10004, is a novel and potent small-molecule inhibitor of phosphodiesterase 4 (PDE4), a key enzyme involved in cyclic adenosine monophosphate (cAMP) degradation and cytokine production of inflammatory cells.

Een reactie achterlaten

Je e-mailadres zal niet getoond worden.